Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 crossover study of BMS-986231 in heart failure with impaired systolic function
2016-003586-26Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cimlanod in heart failure (HF) (3 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Primary: Mean stroke volume index (SVI) by LVOT VTI vs placebo. Started Jul 2017; status: completed.
02
Drugs
cimlanod
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on 2016-003586-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003586-26.